Sandoz, a Novartis division, announced that the European Commission granted marketing authorization in the European Union for a citrate-free high concentration formulation, or HCF, of its biosimilar Hyrimoz. The approval includes all indications covered by the reference medicine: rheumatic diseases, Crohn’s disease, ulcerative colitis, plaque psoriasis, uveitis and hidradenitis suppurativa. Rebecca Guntern, Head of Region Europe, Sandoz, said: "With eight marketed biosimilars Sandoz is offering the broadest biosimilar portfolio and is the leading biosimilars company in Europe with more than two decades of experience. Today’s approval brings Sandoz one step closer to providing European patients with chronic conditions an additional treatment option that offers increased convenience and a reduction in injection volume."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVS:
- Novartis’ Entresto receives positive CHMP opinion for pediatric heart failure
- Novartis upgraded to Outperform from Neutral at Oddo BHF
- Bicycle Therapeutics announces strategic collaboration with Novartis
- Novartis price target raised to CHF 104 from CHF 97 at BofA
- Novartis upgraded to Hold at Deutsche Bank after Kisqali’s ‘positive surprise’